I think we are realistic enough to know that major players receive considerations the “upstarts” are denied.

A much steeper path to tread.

Covid levels the field a bit, as the majors have had nothing but failures.

Positive efficacy data and all is good. AF, the shorts, et al can all go eat S***. I’ll be happy to buy.

Until then, we are really stuck in a tough spot. I’m not selling, but also no enjoying the experience of waiting while manipulators are pretty well ruling the roost.

I remain optimistic that “next week“, will be next week for results, rather than the oft repeated “very soon”.